Tarveda Therapeutics to Present at the 2020 Biotech Showcase

WATERTOWN, Mass.--()--Tarveda Therapeutics, Inc., a clinical stage biopharmaceutical company developing a new class of potent and selective precision oncology medicines, which it refers to as Pentarin® miniature drug conjugates, today announced that Drew Fromkin, President and Chief Executive Officer, will present at the 2020 Biotech Showcase, occurring January 13-15, 2020 at the Hilton Union Square in San Francisco, CA.

The presentation will take place at 9:45am Pacific Time on Tuesday, January 14 in Franciscan B (Ballroom Level).

About Tarveda Therapeutics®, Inc.

Tarveda Therapeutics is a clinical stage biopharmaceutical company developing a new class of potent and selective precision oncology medicines, which it refers to as Pentarin® miniature drug conjugates, for the treatment of patients with various solid tumor malignancies. Tarveda currently has two Pentarin miniature drug conjugates in clinical trials. Its first clinical program, PEN-866, is its initial candidate from its Heat Shock Protein 90 (HSP90) binding miniature drug conjugate platform. HSP90 is a molecular chaperone that is highly activated in the harsh tumor environment across a wide range of solid tumor cancers, but which remains relatively dormant in normal tissue. PEN-866 is currently completing its Phase 1 dose escalation portion of its “all comers” trial of various types of solid tumors and is anticipating conclusion of this Phase 1 dose escalation study in the first quarter of 2020. Tarveda’s second clinical program, PEN-221, is a Pentarin miniature drug conjugate currently in clinical evaluation for the treatment of patients with solid tumors expressing somatostatin receptor 2, or SSTR2, on the cell surface such as neuroendocrine tumors and small cell lung cancer. PEN-221 is a proprietary asset discovered in-house and is currently progressing through its Phase 2a trial. For more information regarding Tarveda, go to: https://www.tarvedatx.com/.

Contacts

Amanda Houlihan
MacDougall
781-591-3484
ahoulihan@macbiocom.com

Release Summary

Tarveda Therapeutics announces that Drew Fromkin, President and CEO, will present at the 2020 Biotech Showcase at 9:45am PT on January 14.

Contacts

Amanda Houlihan
MacDougall
781-591-3484
ahoulihan@macbiocom.com